Cannabis and the Immune System: How Cannabinoids Modulate Immunity

The Immune System and the Endocannabinoid System: A Deep Connection

• CB2 receptors are expressed on virtually every type of immune cell
• Endocannabinoids regulate the production and release of cytokines — chemical messengers of inflammation
• The ECS modulates both innate immunity (first-line defence) and adaptive immunity (targeted response)
• Immune cells themselves produce endocannabinoids, creating a local immunomodulatory feedback loop
• Disruption of the ECS is associated with autoimmune conditions and chronic inflammation

The relationship between the endocannabinoid system and immunity is one of the most clinically significant areas in cannabinoid medicine. CB2 receptors — once thought to be exclusively peripheral — are now known to be expressed on macrophages, T-cells, B-cells, natural killer cells, and mast cells. This distribution allows cannabis-derived cannabinoids to influence the immune response in nuanced and potentially therapeutic ways.

Anti-Inflammatory Properties of Cannabinoids

• THC and CBD both reduce the production of pro-inflammatory cytokines including TNF-alpha, IL-1beta, and IL-6
• CBD inhibits the NF-kB signalling pathway — a master regulator of inflammatory gene expression
• CBG (cannabigerol) has demonstrated potent anti-inflammatory activity in intestinal inflammation models
• Cannabis terpenes (beta-caryophyllene, myrcene) also activate CB2 receptors, amplifying anti-inflammatory effects
• Topical cannabinoid preparations act locally on skin immune cells without systemic effects

The anti-inflammatory properties of cannabinoids are among the best-documented in the scientific literature. Multiple mechanisms contribute — from direct cytokine suppression to modulation of immune cell migration and activation. This broad anti-inflammatory action underpins the clinical interest in cannabis for conditions ranging from inflammatory bowel disease and rheumatoid arthritis to neuroinflammatory disorders.

Autoimmune Conditions and Cannabis: Promise and Caution

• Autoimmune conditions involve inappropriate immune activation — theoretically addressable by immunomodulatory cannabinoids
• Multiple sclerosis, lupus, rheumatoid arthritis, and IBD are areas of active cannabis research
• Sativex (THC:CBD) is licensed for MS spasticity — an autoimmune condition with immune-mediated pathology
• However, immunosuppression from cannabis is not equivalent to pharmaceutical DMTs — do not substitute
• Patients on biologics should disclose cannabis use to their specialist — drug interactions are possible

Medical cannabis should not be viewed as a disease-modifying therapy for autoimmune conditions in the same way as biologics or DMARDs. Its role is symptomatic — reducing pain, inflammation, fatigue, and sleep disruption — rather than halting underlying disease progression. Used as part of a comprehensive autoimmune management plan, however, it can significantly improve quality of life for patients who are inadequately controlled on standard treatments.

Cancer, Immunotherapy, and Cannabinoids: A Complex Relationship

• Preclinical studies show cannabinoids can inhibit tumour cell proliferation and promote apoptosis
• Cannabis may enhance or interfere with checkpoint inhibitor immunotherapy — research is ongoing
• CBD has demonstrated synergistic effects with certain chemotherapy agents in laboratory settings
• Symptom control (pain, nausea, anorexia) via cannabis may preserve immune function during chemotherapy
• Oncologists should be informed of cannabis use — particularly in patients on immunotherapy

The interaction between cannabis and cancer immunotherapy is one of the most actively researched areas in oncological cannabinoid medicine. While the preclinical data on direct antitumour effects is intriguing, clinical evidence remains limited. The clearest role for cannabis in oncology currently is symptom management — with the additional potential that symptom control itself supports immune resilience during cancer treatment.